Diabetic Nephropathy: What Causes to Treat?

REFERENCES

• Sawicki PT, Bender R, Didjurgeit U, Heinemann L, Milhlhauser I, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126–31.
   PubMed Web of Science ®Google Scholar
• Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41: 745–59.
   PubMed Web of Science ®Google Scholar
• Prete DD, Anglani F, Forino M, Ceol M, Fioretto P. Nosadini R, et al. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabeto-logia 1997; 40: 1449–54.
   Google Scholar
• Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, et al. Formation of immunochem-ical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824–9.
   Google Scholar
• Sundkvist G, Lilja B. Autonomic neuropathy predicts deterioration in glomerular filtration rate in patients with IDDM. Diabetes Care 1993; 16: 773–9.
   PubMed Web of Science ®Google Scholar
• Paller MS, Hostetter TH. Dietary protein increases plasma renin and reduces pressor reactivity to angio-tensin II. Am J Physiol 1986; 251: F34–9.
   PubMedGoogle Scholar
• Torffvit O, Adamsson M, Edvinsson L. Renal arterial reactivity to potassium, noradrenaline and neuropeptide Y and association with urinary albumin excretion in the diabetic rat. J Diabetes Complications 1997; 11: 279–86.
   Google Scholar
• Torffvit O, Edvinsson L. Blockade of nitric oxide decreases the renal vasodilatory effect of neuropeptide Y in the insulin-treated diabetic rat. Pflugers Arch 1997; 434: 445–50.
   PubMed Web of Science ®Google Scholar
• Parving H-H, Nielsen FS, Bang LE, Smidt UM, Svendsen TL, Chen J-W, et al. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia 1996; 39: 1590–7.
   Google Scholar
• Van den Born J, van Kraats AA, Bakker MAH, Assmann KJM, Dijkman HBPM, van der Laak JAWM, et al. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. Diabetologia 1995; 38: 1169–75.
   PubMed Web of Science ®Google Scholar
• Solini A, Ricci F, Vergnani L, Crepaldi G. Glycosami-noglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 819–23.
   PubMed Web of Science ®Google Scholar
• Torffvit O, Jorgensen PE, Kamper A-L, Holstein-Rathlou N-H, Leyssac PP, Poulsen SS, et al. Urinary excretion of Tamm-Horsfall protein and epidermal growth factor in chronic nephropathy. Nephron 1998; 79: 167–72.
   Google Scholar
• Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27: 765–75.
   PubMed Web of Science ®Google Scholar
• Bouby N, Trinh-Trang-Tan M-M, Kriz W, Bankir L. Possible role of the thick ascending limb and of the urine concentrating mechanism in the protein-induced in-crease in GFR and kidney mass. Kidney Int 1987; 32: S57–61.
   PubMed Web of Science ®Google Scholar
• Ong ACM, Fine LG. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: implications for human renal disease progres-sion. Am J Kidney Dis 1994; 23: 205–9.
   PubMed Web of Science ®Google Scholar
• Derylo B, Babazono T, Glogowski E, Kapor-Drezgic J, Hohman T, Whiteside C. High glucose-induced mesan- gial cell altered contractility: role of the polyol pathway. Diabetologia 1998; 41: 507–15.
   Google Scholar
• Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993; 22: 72–82.
   PubMed Web of Science ®Google Scholar
• Fagot-Campagna A, Nelson RG, Knowler WC, Pettitt DJ, Robbins DC, Go O, et al. Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: the Strong Heart Study. Diabetologia 1998; 41: 1002–9.
   Google Scholar
• Mathiesen ER, Ronn B, Jensen T, Strom B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245–9.
   Google Scholar
• Paulsen EP, Burke BA, Vernier RL, Mallare MJ, limes DJ, Sturgill BC. Juxtaglomerular body abnormalities in youth-onset diabetic subjects. Kidney Int 1994; 45: 1132–9.
   PubMed Web of Science ®Google Scholar
• Chagnac A, Gafter U, Zevin D, Hirsch Y, Markowitz I, Levi J. Enalapril attenuates glomerular hyperfiltration following a meat meal. Nephron 1989; 51: 466–9.
   PubMed Web of Science ®Google Scholar
• Nielsen FS, Rossing P, Gall M-A, Smidt UM, Chen JVV, Sato A, et al. Lisinopril improves endothelial dysfunc-tion in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest 1997; 57: 427–34.
   Google Scholar
• Tajiri Y, Umeda F, Inoguchi T, Kunisaki M, Nawata H, Ninomiya H, et al. Effects of captopril on urinary excretion of albumin and pro staglandins in patients with diabetic nephropathy. Diabetes Res 1990; 13: 145–50.
   PubMedGoogle Scholar
• Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991; 45: 119–31.
   Google Scholar
• Stenvinkel P. Bolinder J, Alvestrand A. Short-term treatment with ramipril normalizes renal haemody-namics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. Acta Diabetol 1997; 34: 10–7.
   Google Scholar
• Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 1996; 49: 1110–9.
   PubMed Web of Science ®Google Scholar
• Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 1996; 14: 601–7.
   Google Scholar
• Jenkins DAS, Cowan P, Collier A, Watson ML, Clarke BF. Blood glucose control determines the renal haemodynamic response to angiotensin converting enzyme inhibition in Type 1 diabetes. Diabetic Med 1990; 7: 252–7.
   Google Scholar
• Vuorinen-Markkola H, Yki-Järvinen H. Antihyperten-sive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non- insulin-dependent diabetes mellitus. Metabolism 1995; 44: 85–9.
   PubMed Web of Science ®Google Scholar
• Costa FV, Borghi C, Mussi A, Ambrosioni E. Hypolipi-demic effects of long-term antihypertensive treatment with captopril. A prospective study. Am J Med 1988; 84 (Suppl 3A): 159–61.
   Google Scholar
• Mathiesen ER, Ronn B, Strom B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabetic Med 1995; 12: 482–7.
   Google Scholar
• Hasslacher Ch, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1985; 28: 6–11.
   PubMed Web of Science ®Google Scholar
• Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis EJ, Cooper M, et al, and the collaborative Study Group. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996; 50: 1651–8.
   Google Scholar
• Sampson MJ, Griffith VS, Drury PL. Blood pressure, diet and the progression of nephropathy in patients with type 1 diabetes and hypertension. Diabetic Med 1994; 11: 150–4.
   Google Scholar
• Sawicki PT, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933–8.
   PubMed Web of Science ®Google Scholar
• Gall MA, Hougaard P. Borch-Johnsen K, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783–8.
   Google Scholar
• Nelson RG, Knowler WC, McCance DR, Sievers ML, Pettitt DJ, Charles MA, et al. Determinants of end-stage renal disease in Pima indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabeto-logia 1993; 36: 1087–1093.
   PubMedGoogle Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascualr and micro-vascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
   Google Scholar
• Baba T, Murabayashi S, Tomiyama T, Takebe K. Uncontrolled hypertension is associated with a rapid progression of nephropathy in Type 2 diabetic patients with proteinuria and preserved renal function. Tohuku J Exp Med 1990; 161: 311–8.
   PubMed Web of Science ®Google Scholar
• Ravid M, Savin H, Lang R, Junin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch Intern Med 1992; 152: 1225–9.
   PubMedGoogle Scholar
• Schmitz A, Vwth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994; 37: 1251–8.
   Google Scholar